SLO-NIACIN 250 mg by Upsher-Smith Laboratories — Ingredients, Evidence & Safety

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)

This product received a low safety score because its niacin content is more than seven times the recommended daily upper limit of 35mg.

Label Data

1 Tablet(s) Serving Size

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

250 mg (1250% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 7.1× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 250mg UL 35mg

Other Ingredients

Hypromellose hydrogenated Vegetable Oil Silicon Dioxide Magnesium Stearate Glyceryl Behenate Red 40

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions 250 mg: Adults - one Slo-Niacin tablet morning or evening, or as directed by a physician. Do not crush or chew.

⚠️ Warnings & Precautions

Please refer to insert for cautions and warnings.

Keep out of reach of children.

🧪 Formulation Notes

This starter-kit will help you get started on Slo-Niacin.

Additional Information

Clinically proven to support good cholesterol (HDL) Starter kit

250 mg each

Helps maintain good cholesterol (HDL) within the normal range.

Store at controlled room temperature, 15 - 30(0)C (59-86(0)F).

Find a store and additional product information at www.slo-niacin.com

1. Data on file. Upsher-Smith Laboratories, Inc.

Product Details

UPC / SKU 3 0245-0062-20 2

DSLD Entry Date 2019-09-24

Product Type Vitamin

Form Tablet or Pill

Brand Upsher-Smith Laboratories

DSLD ID 206207

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →